IJCM  Vol.6 No.11 , November 2015
Serum and Blister Fluid Pharmacokinetics of Amikacin in Severe Burn Patients
ABSTRACT
Objective: To characterize amikacin pharmacokinetics in serum and in blister fluid of severe burn patients to guide optimal treatment timing. Methods: Patients (N = 32) were divided into four groups based on amikacin administration timing and groups received drug minutes to hours after injury. In Groups A, B, C, and D, amikacin (400 mg, IV) was administered 3 - 4, 10, 20 and 30 h post burn injury, respectively (N = 8 for all groups). Next blister fluid and venous blood samples from 9 patients were obtained at 0, 0.25, 0.5, 1, 2, 3, 4, 5, 6, and 7 h after drug infusion. Amikacin concentrations were measured with a fluorescent polarization immunoassay and pharmacokinetics was deduced using DAS3.2.5. Statistical analyses performed with SPSS13.0. Results: Compared with normal values, t1/2z of amikacin from burn patients was shortened in serum but amikacin half-lives in blister fluid was significantly greater than serum half-life values (p < 0.05). Groups A and B had greater pharmacokinetic values at each time point, and Group D did not achieve antibacterial concentrations of amikacin. Conclusion: Early amikacin administration in severe burn patients offers greater concentrations of drug in serum and blister fluids.

Cite this paper
Hua, R. , Xu, H. , Rong, X. and Yang, R. (2015) Serum and Blister Fluid Pharmacokinetics of Amikacin in Severe Burn Patients. International Journal of Clinical Medicine, 6, 852-858. doi: 10.4236/ijcm.2015.611112.
References
[1]   Schwacha, M.G., Knöferl, M.W. and Chaudry, I.H. (2000) Does Burn Wound Excision after Thermal Injury Attenuate Subsequent Macrophage Hyperactivity and Immunosuppression? Shock, 14, 623-628.
http://dx.doi.org/10.1097/00024382-200014060-00009

[2]   Rong, X.Z., Zhang, W.Z. and Ren, J.L. (2001) A Clinical Observation of Early Short Term Use of Potent Antibiotics in Severely Burned Patients. Journal of Medical Colleges of PLA, 16, 252-254.

[3]   Yang, R.H., Rong, X.Z., Hua, R., et al. (2009) Pharmacokinetics of Vancomycin and Amikacin in the Subeschar Tissue Fluid in Patients with Severe Burn. Burns, 35, 75-79.
http://dx.doi.org/10.1016/j.burns.2008.05.016

[4]   Boucher, B.A., Kuhl, D.A. and Hickerson, W.L. (1992) Pharmacokinetics of Systemically Administered Antibiotics in Patients with Thermal Injury. Clinical Infectious Diseases, 14, 458-463.
http://dx.doi.org/10.1093/clinids/14.2.458

[5]   Jaehde, U. and Sörgel, F. (1995) Clinical Pharmacokinetics in Patients with Burns. Clinical Pharmacokinetics, 29, 15-28.
http://dx.doi.org/10.2165/00003088-199529010-00003

[6]   Varela, J.E., Cohn, S.M., et al. (2000) Pharmacokinetics and Burn Eschar Penetration of Intravenous Ciprofloxacin in Patients with Major Thermal Injuries. Journal of Antimicrobial Chemotherapy, 45, 337-342.
http://dx.doi.org/10.1093/jac/45.3.337

[7]   Peck, M.D. and Ward, C.G. (1997) Burn Injury. In: Civetta, J.M., Taylor, R.W., Kirby, R.R., Eds., Critical Care, Lippincott-Raven Publishers, Philadelphia, 1265-1275.

[8]   Sangil, J., Seunghoon, H., Jongtae, L., et al. (2014) Population Pharmacokinetic Analysis of Piperacillin in Burn Patients. Journal of Antimicrobial Chemotherapy, 58, 3744-3751.
http://dx.doi.org/10.1128/AAC.02089-13

[9]   Kevin, S.A., Matthew, P.R., Krista, L., et al. (2015) Colistin Pharmacokinetics in Burn Patients during Continuous Venovenous Hemofiltration. Journal of Antimicrobial Chemo-therapy, 59, 46-52.
http://dx.doi.org/10.1128/AAC.03783-14

[10]   Tally, F.P., Louie, T.J., Weinstein, W.M., et al. (1975) Amikacin Therapy for Severe Gram-Negative SepsisEmphasis on Infections with Gentamicin-Resistant Organisms. Annals of Internal Medicine, 83, 484-488.
http://dx.doi.org/10.7326/0003-4819-83-4-484

[11]   Hu, B.J., Chen, X.H. and Ni, C.M. (1999) The Evaluation and the Result of 12 Antibiotics Sensitive to Nosocomial Infection Bacteria. Chin J Nosocomiol, 9, 118-120.

[12]   Dou, Y., Zhang, Q. and Liao, Z.J. (2004) Investigation on the Drug Resistance of Pseudomonas aeruginosa in Our Burn Ward in the Past 11 Years. Chinese Journal of Burns, 20, 6-9.

[13]   Shi, Y.G., Zhang, Y.Y., Zhang, J., Wang, Z.P., Yu, J.C. and Wang, F. (2001) Pharmacokinetics of Antimicrobial Agents in the Elderly. Chinese Journal of Infection and Chemotherapy, 1, 3-6.

[14]   Zaske, D.E., Sawchuk, R.J. and Strate, R.G. (1978) The Necessity of Increased Doses of Amikacin in Burn Patients. Surgery, 84, 603-608.

[15]   Bonapace, C.R., White, R.L., Friedrich, L.V., Norcross, E.D. and Bosso, J.A. (1999) Pharmacokinetics of Cefepime in Patients with Thermal Burn Injury. Antimicrobial Agents and Chemotherapy, 43, 2848-2854.

[16]   Bourget, P., Lesne-Hulin, A., Le Reveillé, R., Le Bever, H. and Carsin, H. (1996) Clinical Pharmacokinetics of Piperacillin-Tazabactam Combination in Patients with Major Burns and Signs of Infection. Antimicrobial Agents and Chemotherapy, 40, 139-145.

 
 
Top